Adagene AAQS

What does Adagene do? Adagene Inc. develops monoclonal antibody drugs for cancer treatment in China, focusing on clinical-stage products. Its lead candidate ADG126, a masked anti-CTLA-4 mAb, is in phase 1b/2 trials for cancer. The company also advances ADG116, a fully human anti-CTLA-4 antibody using NEObody technology, in phase 1b/2 for solid tumors. ADG206 targets advanced metastatic solid tumors in phase 1, while ADG104, an anti-PD-L1 antibody, is in phase 2 development. Additional candidates include ADG125 for phase 2 studies, ADG138 for low-expressing tumors, and ADG152 for off-tumor toxicities, all in preclinical stages. The company's pipeline targets various cancer types through innovative antibody technologies. Adagene generates revenue through the development and commercialization of its antibody drug candidates. It focuses on clinical trials for products like ADG126, ADG116, and ADG104, aiming to secure partnerships with pharmaceutical companies for later-stage development and marketing. The company's products target advanced cancer treatments, appealing to oncology-focused pharmaceutical firms seeking novel therapies. ADG153, a masked anti-CD47 antibody, and CD28 T-cell engagers represent further pipeline opportunities for collaboration in oncology drug development. Adagene's business model centers on advancing its pipeline through clinical trials to attract potential partners. The company's focus on anti-CTLA-4, anti-PD-L1, and novel antibody technologies positions it for strategic collaborations. Its products target unmet needs in cancer treatment, particularly for resistant or metastatic tumors. The company's preclinical and clinical-stage candidates, including ADG138 and ADG152, are designed to address specific oncology challenges, making them attractive for pharmaceutical partnerships. Adagene is one of the most popular companies on Eulerpool.